Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 19,416 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Combination Clear all
Active, not recruiting Phase 2 Interventional Results available

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

NCT01723774
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility

NCT03401918
View directory record Official record
Conditions
Recurrent Pregnancy Loss, Unexplained Infertility
Interventions
Uterine ERA and microbiome testing, Oral antibiotics and vaginal probiotics
Diagnostic Test · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Predictive Analytics and Computer Visualization Enhances Patient Safety to Prevent Falls

NCT06339125
View directory record Official record
Conditions
Fall Patients, Fall Injury
Interventions
Fall prevention algorithm, Inspiren camera visualization
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
5,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

NCT04585789
View directory record Official record
Conditions
Hepatitis B
Interventions
JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered

NCT01068743
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
saxagliptin, metformin, saxagliptin + metformin (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 23, 2026, 5:29 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

NCT04396535
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Bintrafusp Alfa, Docetaxel
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Not applicable Interventional

Combining Restrictive Guidelines and a NIRS SCORE to Decrease RBC Transfusions

NCT02535208
View directory record Official record
Conditions
Anemia of Prematurity (AOP)
Interventions
Restrictive transfusions based on SCOR assessment, Liberal transfusions
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 3 Days
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 23, 2026, 5:29 AM EDT
Active, not recruiting Not applicable Interventional

Interventions for English Language Learners At-Risk for ADHD

NCT05918991
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daily Report Card, Language Intervention
Behavioral · Other
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 1 Interventional

Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis

NCT03929068
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
carbidopa-levodopa, Placebo Oral Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 2 Interventional

A Study of Disease Progression and Anti-HIV Treatments

NCT00001068
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Not applicable Interventional

Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)

NCT04522791
View directory record Official record
Conditions
Mild Cognitive Impairment, Healthy Aging
Interventions
RFB, VSOP, IR
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
60 Years to 89 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 5:29 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study

NCT04837118
View directory record Official record
Conditions
Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

NCT02220218
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC), Canagliflozin, Metformin IR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT01306617
View directory record Official record
Conditions
Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus
Interventions
ABT-450, ABT-333, ribavirin, ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

NCT01888874
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GLPG0634, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
28
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

NCT05936489
View directory record Official record
Conditions
Eye Diseases, Presbyopia, Refractive Errors, Brimonidine Tartrate, Aceclidine, Ophthalmic Solutions
Interventions
Aceclidine + Brimonidine, Aceclidine
Drug
Lead sponsor
LENZ Therapeutics, Inc
Other
Eligibility
45 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 1 Interventional

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

NCT03335540
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Relatlimab, Cabiralizumab, Ipilimumab, IDO1 Inhibitor, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03654274
View directory record Official record
Conditions
Endometriosis
Interventions
Relugolix, Estradiol/norethindrone acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
60
States / cities
Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

NCT04263350
View directory record Official record
Conditions
Healthy Participants
Interventions
Atazanavir/Cobicistat, Reyataz Atazanavir, Cobicistat
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Not applicable Interventional Results available

Coaching Veterans to Healthy Weights and Wellness

NCT00967668
View directory record Official record
Conditions
Obesity
Interventions
Small change approach to improve physical activity and diet, MOVE! Usual Care
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 2 Interventional

Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases

NCT00068068
View directory record Official record
Conditions
Liver Metastasis, Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
Interventions
Talaporfin sodium (LS11), LED-based light infusion device, Light emitting diodes (LED), Photodynamic therapy, Phototherapy, Chemotherapy
Drug · Device · Procedure
Lead sponsor
Light Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
5
States / cities
Denver, Colorado • Greenville, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2006 · Synced Oct 23, 2026, 5:29 AM EDT
Completed Phase 1Phase 2 Interventional

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

NCT00038168
View directory record Official record
Conditions
Prostate Cancer
Interventions
Estramustine, Taxol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 23, 2026, 5:29 AM EDT
Recruiting Phase 2 Interventional

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

NCT05526989
View directory record Official record
Conditions
Penile Carcinoma
Interventions
Dostarlimab, Niraparib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 23, 2026, 5:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Interventions
Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures, Cisplatin, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 5:29 AM EDT